BCM
DNLI icon

Bayesian Capital Management’s Denali Therapeutics DNLI Stock Holding History

Bayesian Capital Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10,130
Closed -$138K – 623
2025
Q1 		$138K Sell
10,130
-8,690
-46% -$167K 0.02% 523
2024
Q4 		$384K Buy
18,820
+10,820
+135% +$277K 0.05% 433
2024
Q3 		$233K Sell
8,000
-42,500
-84% -$1.05M 0.03% 533
2024
Q2 		$1.17M Buy
50,500
+28,700
+132% +$551K 0.13% 202
2024
Q1 		$447K Buy
+21,800
New +$410K 0.04% 462
2023
Q4 		– Sell
-13,942
Closed -$288K – 819
2023
Q3 		$288K Buy
+13,942
New +$354K 0.03% 477

Other funds holding DNLI

BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $29.7B AUM 13.98% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return